HCW Biologics Inc., a clinical-stage biopharmaceutical company, has announced the pricing of its follow-on offering, raising approximately $5.0 million through the sale of 671,140 units at $7.45 each. Each unit consists of one share of common stock and two warrants for additional shares, with the warrants exercisable immediately and expiring in five years. The proceeds will support preclinical and clinical development, business development, patent portfolio expansion, research, and general corporate purposes. Maxim Group LLC is serving as the sole placement agent for the offering.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.